What is BPC-157?

A synthetic 15-amino-acid peptide whose sequence is described as a partial sequence of a protein found in human gastric juice.

At a glance

What it is
A synthetic 15-amino-acid peptide whose sequence is described as a partial sequence of a protein found in human gastric juice.
Also called
Body Protection Compound-157 · Pentadecapeptide BPC 157 · PL 14736 · BPC-157 acetate · BPC-157 free base · Bepecin
US status
HHS discretionHHS says it does not intend to act against 503A compounding that meets its conditions. That is not an approval.
Evidence
C: Small or uncontrolled human dataA handful of small human studies with no control group, plus a meeting abstract; we found no published randomized controlled trial in people.
Safety signal
Theoretical risk named by FDA or reviewsFDA has named immunogenicity, impurity and characterization problems, and "no, or only limited" safety data.

Status checked Nov 16, 2026 · Draft policy

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Randomized controlled trials32Measured: tolerability and blood levels in 32 healthy people randomized to BPC-157 (24) or placebo (8) by rectal enema, once, then daily for 7 days after a 1-week break; reported only in meeting abstracts (Veljaca 2002/2003, PL 14736 Phase 1).33
Randomized controlled trials53Measured: the Disease Activity Index, not clearly defined, in 53 people with ulcerative colitis randomized 1:1 by rectal enema for 2 weeks, 46 of whom completed; reported only in a meeting abstract (Ruenzi 2005).33
Open-label studies12Measured: symptoms on the Global Response Assessment in 12 women aged 39 to 76 after a single injection into the bladder wall during cystoscopy (Lee, Walker and Ayadi 2024).13
Observational studies16Measured: pain relief as patients rated it by phone, with no validated tools, in 16 of 17 people identified (12 given BPC-157 only, 4 BPC-157 with another peptide) after injections into the knee joint, in a look back at one year of charts (2019-2020), most injections 6 months to 1 year before the call (Lee & Padgett 2021).39

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Case reports and series2Measured: heart, liver, kidney, thyroid and glucose blood markers and vital signs in 2 people (a man of 58 and a woman of 68), both given IV BPC-157 before, after an IV infusion over 1 hour, across 3 days (Lee & Burgess 2025).40
Registered trials42Registered trial NCT02637284 (PCO-02) of an oral "Bepecin" tablet, about 42 people planned, over 2 weeks (Phase 1b), to measure adverse events at 6 months; nothing has been posted from it.52
Registered trials120Registered trial NCT07437547 (Phase 2, recruiting since February 2, 2026, sponsor Hudson Biotech): 120 people planned with an acute grade II hamstring strain, randomized and quadruple-blind to BPC-157 or placebo injected under the skin once daily for 14 days, to measure return to sport at 8 weeks and injury size on MRI at day 14; the amount given is not stated.52
Registered trials30Registered trial NCT07803250 (Phase 1, not yet recruiting, estimated start January 1, 2027, sponsor University of Arkansas): 30 people planned (the summary says 20) after rotator cuff repair, randomized and quadruple-blind to BPC-157 or saline self-injected under the skin once daily for 90 days, to measure shoulder strength at the start, at 12 weeks and at 5 months; the amount given is not stated.52
Registered trials40Registered trial NCT07752381 (no phase, completed November 2025, sponsor Parlay Wellness, a seller): hs-CRP, IL-6 and self-rated swelling in 40 adults taking oral gummies for 8 weeks, in one group with no control; nothing has been posted from it.52
Reviews30A 2026 systematic review registered with PROSPERO (searched to June 1, 2026) found 3 human studies with 30 people in all (knee 16, bladder 12, IV 2), and rated all of them poor quality and the certainty of evidence "very low". We found no new human outcome study from 2025 or 2026 in PubMed, and a June 2026 orthopedic review agrees that the human musculoskeletal evidence is one small series with no control group.4165
ReviewsNot statedA 2025 review in the HSS Journal included 36 studies of musculoskeletal outcomes: 35 preclinical and 1 clinical.11

What programs claim, and what has been studied

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Accelerates healing / soft-tissue (tendon, ligament, muscle) repairAnimal studies (35 preclinical) and one look back at the charts of 12 people given knee injections, with no control group.112930D
Reduces inflammationOnly animal studies for inflammation across the body.111229D
Gut protection / GI healing / ulcerative colitisOne decades-old meeting abstract on ulcerative colitis, plus animal studies.233031D
Relieves knee or joint painOne look back at the charts of 12 people, with no control group.1126C

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Resolves interstitial cystitis symptomsOne pilot study of 12 people, with no control group.13C
Nerve regeneration / reduces neuropathic painAnimal studies only.1129D
Increases angiogenesis (framed as a benefit)Animal studies only; FDA reviewers, as law firms reported, named angiogenesis a theoretical risk.12212932D
"In clinical trials patients reported faster recovery"We found no published controlled trial that reports this.111229F
"Generally well-tolerated, minimal side effects" / "safe"There are no clinical safety data, and the FDA says its information is limited.4112930F
"Full regenerative effect" about 90 daysWe found no evidence.29F
"Enhanced bioavailability" (FlexMax / oral)None in humans; HHS calls oral peptide bioavailability "inherently difficult".329F
">99% purity" (RUO)A seller's claim; an independent dataset found products that failed identity and amounts that varied widely from the label.153132Unverified

Safety facts

Reports to the FDA

  • The FDA's adverse event database (FAERS, data to October 28, 2026) holds 24 reports that list "BPC-157", 21 of them flagged serious; the flags and the other drugs in the reports mean they do not show that BPC-157 caused the events. The most frequent terms are shortness of breath (dyspnoea), redness (erythema), headache and "drug ineffective" (3 each), then hypersensitivity, dizziness, nausea and flushing (2 each); the FDA's advisory committee review cited 3 FAERS cases, including shortness of breath, and darkened skin (hyperpigmentation) after a "research use only" blend of BPC-157 and another peptide.723
  • FAERS (data through October 28, 2026) holds 26 reports in all: "BPC-157" and "BPC 157" each return the same 24, and "BPC157" returns 2.53
  • The FDA's advisory committee review found three FAERS reports, all for injected BPC-157. One concerned a blend of BPC-157 and another peptide from Cellular Peptide LLC, labeled "research purposes only", and described darkened skin (hyperpigmentation) that came back when the product was taken again.33

What the FDA has said

  • The FDA says BPC-157 "may pose risk for immunogenicity" (immune reactions) by some routes, and that its impurities and characterization are complex.4
  • The FDA says it has "no, or only limited, safety-related information" for the proposed routes.4
  • The HHS policy does not list a nasal route for BPC-157. The FDA has "strong concerns" about the nasal spray that was nominated, because nothing was known about its pump, container or closure, and says injected or nasal use "may pose a significant risk for immunogenicity"; no human nasal study exists.3161733
  • In a footnote, the FDA explains that carcinogenicity studies are expected when a drug is used for 6 months or more of a person's life in total.33
  • Angiogenesis (new blood vessel growth) appears in the FDA's text only as a hypothesized healing mechanism ("induce angiogenesis"); the FDA's written evaluation does not call it a tumor risk.3334
  • The FDA says that as a 15-amino-acid peptide given by injection or nasal spray, BPC-157 "may pose a significant risk for immunogenicity."33
  • The FDA's overall finding: "insufficient clinical safety information to characterize the safety profile."33

In studies and reviews

  • The FDA said none of the human reports appears to describe serious adverse events, but the studies were short and small, used amounts "likely exploratory," and mostly did not make their safety monitoring clear.33
  • In three standard genetic toxicity tests, BPC-157 free base did not cause mutations; the FDA relays the authors' conclusion "BPC-157 is not a mutagen."33
  • In 28-day studies of injections into muscle in rats and dogs, the FDA found "clinically relevant safety signals": changes in clotting time (aPTT shorter in rats, longer in dogs) and liver-related signals (higher ALT, glucose and triglycerides). No longer studies exist.33
  • Injections into muscle on days 6 to 15 of pregnancy in rats caused no fetal malformations. No study covers the full reproductive cycle.33
  • Peer-reviewed authors raise a cancer question: a 2025 letter calls pro-angiogenic signaling a "plausible tumor-promoting hazard", and a 2026 Missouri Medicine review lists "pathological angiogenesis" and "carcinogenesis" among possible risks of unapproved peptides. These are hypotheses, not cases seen in people.1266

No data

  • The FDA found no study that gave BPC-157 to people by mouth, under the skin, through the nose or through the skin.33
  • A 2025 systematic review found "No clinical safety data". Side-effect data in animals cover at most 6 weeks, and the half-life in animals is under 30 minutes.11
  • There are no data on pregnancy, breastfeeding, people under 18, people with a history of cancer, long-term use or repeated use; for the first five, we found no human data. One program excludes pregnancy, breastfeeding and under-18s, and flags a history of cancer.111226
  • We found no published study in PubMed of how oral BPC-157 is absorbed, in animals or humans. The FDA says its pharmacokinetic profiles by mouth, rectally, under the skin, through the nose and through the skin "are unknown at this time," and that it "found no human pharmacokinetic data" by mouth, under the skin, through the nose or through the skin.333454
  • The FDA found no carcinogenicity (cancer) studies of BPC-157, in its free base or acetate form.33

Product quality

  • A 2026 preprint, not peer-reviewed, analyzed a voluntary third-party testing dataset of "research use only" peptides: 3.5% of BPC-157 reports failed identity (they did not contain the stated peptide), BPC-157 had one of the widest spreads of measured amount against the label (interquartile range 94% to 115%), and 15% of endotoxin-tested samples across all peptides had measurable endotoxin. The FDA found few certificates of analysis tested for impurities, aggregates or endotoxin, and found products sold under the name that contained different active moieties.152123
  • Most BPC-157 certificates of analysis the FDA found "only contain purity testing results", with no impurity limits.33
  • The FDA found nothing on bioburden, endotoxin or residual solvents for BPC-157 free base.33
  • The FDA has seen "multiple salts, and derivatives, including different active moieties" sold under the name BPC-157.33
  • A 2026 preprint, not peer-reviewed, counts 17 BPC-157 reports that did not contain the stated peptide.63

Compounded BPC-157 is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

  • Names the pharmacy that compounds it: a state-licensed 503A pharmacy (or a physician or federal facility), with a state license you can look up2LegalGood practice
  • Says clearly that the product is not FDA-approved and that the FDA has not reviewed its safety, effectiveness or quality122627Good practice
  • Says the HHS policy is enforcement discretion, not approval, and could be revisited2Good practice
  • Makes no claim to treat or cure a disease, and describes the evidence honestly: mostly animal studies, with small human data924Good practice
  • Has a safety page with side effects, who should not take it (pregnancy, under-18s, a history of cancer) and when to seek care26Good practice
  • Follows up with check-ins, and lab tests where appropriate27Good practice
  • Ships only to states where it is permitted to operate, and lists the states it excludes27Good practice
  • Refunds you if you are not prescribed, and states its subscription and cancellation terms clearly262728Good practice
  • Warns tested athletes that WADA prohibits BPC-157 (class S0)6Good practice
  • Does not sell or link to "research use only" peptides924LegalGood practice

The conditions of the HHS policy

The policy covers a compounded product only when all of its conditions are met.

  1. Uses only a peptide listed in Appendix A of the HHS policy23Legal
  2. Matches the form and routes HHS lists: given only under the skin, into muscle, by mouth or on the skin, never through the nose, by IV or by another route3Legal
  3. Gets the active ingredient from an FDA-registered (section 510) facility, with a valid certificate of analysis for each lot covering identity, purity, potency, endotoxins, heavy metals, microbes and impurities, and names the original manufacturer23LegalGood practice
  4. Names an original manufacturer that is FDA-registered (section 510) and follows CGMP, with its location on the certificate of analysis; any repacker or reseller has validated the manufacturer and the certificate23Legal
  5. Explains on the patient labeling how to report side effects (MedWatch), and the pharmacy reports products compounded, serious adverse events and quality problems to the FDA and the states2Legal
  6. Labels the product "This is a compounded drug product. Not for resale."2Legal
  7. Sells BPC-157 acetate as a single active ingredient, with no blends23Legal
  8. For a product taken by mouth, the pharmacy holds documentation of "adequate oral bioavailability in humans"2Legal
  9. Packs only an FDA 510(k)-cleared syringe with the product2Legal
  10. Dispenses only on a valid prescription for one patient, after a licensed clinician evaluates you (no "add to cart" ordering), and meets all other FD&C Act rules, with nothing made under insanitary conditions2Legal

  1. 1.
    Federal Register notice, FR Doc. 2026-22192, 91 FR 68526 (Oct 30, 2026), HHS OSTier 1: regulator or registergovinfo.govread Nov 16, 2026↩
  2. 2.
  3. 3.
    HHS policy Appendix B (identity and routes)Tier 1: regulator or registerhhs.govread Nov 16, 2026↩
  4. 4.
  5. 5.
    FDA Briefing Document, PCAC July 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  6. 6.
    USADA: BPC-157 substance page (modified Aug 10, 2026)Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
  7. 7.
    openFDA FAERS API query "BPC-157" (data to 2026-10-28)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
  8. 8.
    eCFR 21 CFR Part 1308 (Schedules of controlled substances), as of 10/22/2026Tier 1: regulator or registerecfr.govread Nov 16, 2026↩
  9. 9.
    FDA Warning Letter, Peptide Partners LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  10. 10.
    DoD Operation Supplement Safety: BPC-157 (Apr 29, 2025)Tier 1: regulator or registeropss.orgread Nov 16, 2026↩
  11. 11.
  12. 12.
    Józwiak M et al. Reply to Sikiric et al. Pharmaceuticals 2025;18(10):1451Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
  13. 13.
  14. 14.
    NCT02637284 PCO-02 Safety and Pharmacokinetics Trial (registry mirror)Tier 2: peer-reviewed or trial registryctv.veeva.comread Nov 16, 2026
  15. 15.
  16. 16.
    Holland & Knight: HHS Issues Interim Enforcement Discretion Policy (Nov 4, 2026)Tier 3: reference, law firm or presshklaw.comread Nov 16, 2026↩
  17. 17.
    Venable: HHS Announces Interim Enforcement Discretion… (Nov 2026)Tier 3: reference, law firm or pressvenable.comread Nov 16, 2026↩
  18. 18.
    AJMC: 5 Things to Know About HHS's Interim Peptide Compounding Policy (Oct 29, 2026)Tier 3: reference, law firm or pressajmc.comread Nov 16, 2026↩
  19. 19.
  20. 20.
    Orrick: FDA Announces Removal of 12 Peptides from Category 2 (Apr 2026)Tier 3: reference, law firm or pressorrick.comread Nov 16, 2026↩
  21. 21.
    Bass Berry & Sims: FDA Advisory Committee Recommends Six Peptides…Tier 3: reference, law firm or pressbassberry.comread Nov 16, 2026↩
  22. 22.
    FDA Law Blog (Hyman Phelps): PEPTIDE-L WAVE! PCAC Approves Four… (Jul 2026)Tier 3: reference, law firm or pressthefdalawblog.comread Nov 16, 2026↩
  23. 23.
    Drug Topics: FDA Panel to Evaluate 7 Popular Peptides (Jul 6, 2026)Tier 3: reference, law firm or pressdrugtopics.comread Nov 16, 2026↩
  24. 24.
    Arent Fox Schiff: RUO-ined: Five Peptide Vendors… (Aug 2026)Tier 3: reference, law firm or pressafslaw.comread Nov 16, 2026↩
  25. 25.
    Frier Levitt: Peptides Under the Microscope: FDA and State EnforcementTier 3: reference, law firm or pressfrierlevitt.comread Nov 16, 2026↩
  26. 26.
    HealthRX BPC-157 product pageTier 4: lead onlyhealthrx.comread Nov 16, 2026↩
  27. 27.
    Superpower Peptides pageTier 4: lead onlysuperpower.comread Nov 16, 2026↩
  28. 28.
    LiveVital homepage (no BPC-157 page found)Tier 4: lead onlylivevital.ioread Nov 16, 2026↩
  29. 29.
    Desert Mobile Medical BPC-157 product pageTier 4: lead onlydesertmobilemedical.comread Nov 16, 2026↩
  30. 30.
    FormBlends: Where to Buy BPC-157 OnlineTier 4: lead onlyformblends.comread Nov 16, 2026↩
  31. 31.
    PrimeLab (RUO vendor) BPC-157 10mgTier 4: lead onlyprimelab.us.comread Nov 16, 2026↩
  32. 32.
    Enos Labs USA (RUO vendor) Wolverine BPC/TB-500Tier 4: lead onlyenoslabsusa.comread Nov 16, 2026↩
  33. 33.
  34. 34.
    PCAC Jul 23, 2026: FDA PresentationsTier 1: regulator or registerFDAread Nov 16, 2026↩
  35. 35.
  36. 36.
    Docket HHS-OASH-2026-0496 (documents, comments, docket record)Tier 1: regulator or registerregulations.gov / HHSread Nov 16, 2026↩
  37. 37.
    Federal Register API search: "peptide bulk drug substances", from 2026-07-01Tier 1: regulator or registerFederal Register (OFR/GPO)read Nov 16, 2026
  38. 38.
    Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (Jul 27, 2026)Tier 3: reference, law firm or pressMcDermott Will & Schulteread Nov 16, 2026↩
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
  46. 46.
  47. 47.
  48. 48.
  49. 49.
    Sikirić P et al. A new gastric juice peptide, BPC. J Physiol Paris 1993. PMID 8298609Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
  50. 50.
  51. 51.
  52. 52.
  53. 53.
  54. 54.
    PubMed E-utilities esearch counts (queries as stated in 7b)Tier 1: regulator or registerNCBI / NLMread Nov 16, 2026↩
  55. 55.
  56. 56.
  57. 57.
  58. 58.
    FDA Warning Letter: Warrior Labz SARMs, 655280 (Jun 12, 2023)Tier 1: regulator or registerFDAread Nov 16, 2026↩
  59. 59.
  60. 60.
  61. 61.
    Ohio Board of Pharmacy: Ten Common Prescriber Clinic and Medical Spa Violations (updated 12/8/2025)Tier 1: regulator or registerOhio Board of Pharmacyread Nov 16, 2026↩
  62. 62.
    Louisiana Board of Pharmacy Bulletin 26-01: New Laws, 2026 Regular Session (Jul 10, 2026)Tier 1: regulator or registerLouisiana Board of Pharmacyread Nov 16, 2026↩
  63. 63.
  64. 64.
  65. 65.
  66. 66.
  67. 67.
    Brennan, Manna & Diamond: Ohio Med Spas: Peptide Do's and Do Not's (Apr 29, 2026), pointer to S61Tier 3: reference, law firm or pressBrennan, Manna & Diamondread Nov 16, 2026
  68. 78.
  69. 79.
  70. 80.
  71. 81.
    DEA: Controlled Substances, Alphabetical Order (Nov 12, 2026)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
  72. 82.
  73. 83.

We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.